<DOC>
	<DOCNO>NCT01418742</DOCNO>
	<brief_summary>Skin toxicity treatment patient advance metastatic colorectal cancer ( mCRC ) non-mutated ( wild-type ) KRAS treat panitumumab monotherapy failure fluoropyrimidine- , oxaliplatin- , irinotecan-containing chemotherapy regimen .</brief_summary>
	<brief_title>SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial Skin Toxicity Treatment</brief_title>
	<detailed_description>Because frequency severity panitumumab associate skin toxicity affect patient ' quality life thus threaten patient ' compliance therapy . There urgent need evidence-based treatment recommendation prevention management panitumumab -associated skin toxicity . The study aim compare efficacy safety manageable preemptive treatment oral doxycycline combination supportive topical regimen contain erythromycin cream ( 2 % ) duration 12 week occurrence grade panitumumab induced skin toxicity double-blind , control randomized setting . Basic skin treatment without doxycycline discontinue end study treatment 12 week value 6-10 observed visual analogue scale ( VAS ) , whichever sooner .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients advance metastatic colorectal cancer ( mCRC ) nonmutated ( wildtype ) KRAS plan receive treatment panitumumab monotherapy failure fluoropyrimidine , oxaliplatin , irinotecancontaining chemotherapy regimen without prior treatment epidermal growth factor receptor ( EGFR ) antibody 2 . Man woman 18 year age old 3 . Signed date informed consent start specific protocol procedure 4 . ECOG ( Eastern Cooperative Oncology Group ) performance status 0 , 1 , 2 5 . Bilirubin ≤ 1.5 x ULN , SGOT/SGPT ≤ 2.5 x ULN , AP ≤ 3 x ULN evidence liver metastasis Bilirubin ≤ 3 x ULN , SGOT/SGPT ≤ 5 x ULN , AP ≤ 5 x ULN evidence liver metastases 6 . Women childbearing potential use adequate highly effective method contraception . Since doxycyline may reduce efficacy hormonal contraceptive , woman childbearing potential use doublebarrier method within 4 week first intake study medication , study participation least 6 week last intake study medication even use hormonal contraceptive Women consider childbearing potential unless ≥ 50 year old 2 year amenorrheic unless surgically sterile . 1 . Absence abovelisted inclusion criterion 2 . Any serious medical condition psychiatric illness would interfere patient 's ability sign inform consent form . 3 . Allergic reaction one medication use 4 . Subject allergic panitumumab component panitumumab formulation treatment regimen 5 . Prior treatment EGFR antibody 6 . CYP3A4 enzyme inducer , inhibitor , substrate ( eg , phenytoin , phenobarbital , carbamazepine , ketoconazole , rifampicin , rifabutin , St. John 's Wort ) ≤ 2 week randomization ( itraconazole use caution ) 7 . Subjects hypersensitivity doxycycline , tetracycline , ingredient doxycycline capsule 8 . Systemic treatment antibiotic complete less 7 day prior randomization 9 . Pregnant and/or breastfeed woman 10 . Active participation clinical study previous 4 week 11 . Serious liver function disorder 12 . History , evidence , interstitial pneumonitis pulmonary fibrosis 13 . Person committed institution virtue order issue either judicial administrative authority .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>skin toxicity</keyword>
</DOC>